DNA Ploidy as Surrogate for Biopsy Gleason Score for Preoperative Organ Versus Nonorgan-confined Prostate Cancer Prediction

The results of our study have shown that DNA ploidy can serve as a surrogate biomarker that has the potential to replace biopsy Gleason scores for organ- vs nonorgan-confined PCa prediction.